Fundraising Fox
Infinity Bio
Baltimore, US · Founded 2023 · 3 known investors
Find your way into Infinity Bio
Sign up to see every warm intro you have to Infinity Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Infinity Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Infinity Bio provides immune system analysis through its proprietary MIPSA antibody reactome profiling platform, which identifies the targets of individual immune responses against human viruses, human proteins (autoimmunity), and allergen proteins. The technology, developed at Johns Hopkins University's Laboratory of Precision Immunology, is used for immunology and diagnostics research.
Founders & leadership
Infinity Bio was founded in 2023 by Benjamin Larman.
Board
Investors · 3
Reported raises · per SEC filings
Form D private placements$11.5M disclosed across 3 rounds · 2023–2025
▶$5MraisedAug 2025 · 1 investors · Other Health CareRule 506(b)
- Bill CampbellDirector
- Caroline PopperDirector
- Malek FahemDirector
- H. Benjamin LarmanExecutive Officer, Director
- Herman ScholtzDirector
- Matthew HellauerDirector
- Joy NassifExecutive Officer, Director
- Offering amount
- $7M
- Amount sold
- $5M
- First sale
- Jun 2025
- Incorporated
- Corporation, United States, 2023
- Federal exemptions
- 06b
▶$2MraisedMar 2025 · 2 investors · BiotechnologyRule 506(b)
- Matthew HellauerDirector
- Benjamin LarmanExecutive Officer, Director
- Herman ScholtzDirector
- Joy M NassifExecutive Officer, Director
- Caroline PopperDirector
- Offering amount
- $5M
- Amount sold
- $2M
- First sale
- Feb 2025
- Incorporated
- Corporation, United States, 2023
- Federal exemptions
- 06b
▶$4.5MraisedJun 2024 · 1 investors · BiotechnologyRule 506(b)
- Herman ScholtzDirector
- Joy NassifExecutive Officer, Director
- Matthew HellauerDirector
- Benjamin LarmanExecutive Officer, Director
- Caroline PopperDirector
- Offering amount
- $4.5M
- Amount sold
- $4.5M
- First sale
- Jun 2023
- Incorporated
- Corporation, United States, 2023
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Companies working in the same space as Infinity Bio.
Frequently asked questions
- What does Infinity Bio do?
- Infinity Bio provides immune system analysis through its proprietary MIPSA antibody reactome profiling platform, which identifies the targets of individual immune responses against human viruses, human proteins (autoimmunity), and allergen proteins. The technology, developed at Johns Hopkins University's Laboratory of Precision Immunology, is used for immunology and diagnostics research.
- Who founded Infinity Bio?
- Infinity Bio was founded by Benjamin Larman in 2023.
- Who are Infinity Bio's investors?
- Infinity Bio's investors include Illumina Ventures, TCP Venture Capital, PTX Capital.
- How much funding has Infinity Bio raised?
- Infinity Bio has disclosed $11.5M raised across 3 rounds.
- Where is Infinity Bio headquartered?
- Infinity Bio is headquartered in Baltimore, US.